describ
product
character
human
monoclon
antibodi
mab
specif
major
hepat
b
viru
hbv
protein
mab
two
one
secret
bcell
clone
obtain
peripher
blood
mononuclear
cell
pbmc
one
person
convalesc
acut
hepat
b
one
vaccin
individu
former
recogn
denaturationinsensit
epitop
within
protein
wherea
latter
recogn
denaturationsensit
conform
epitop
locat
within
hbsag
common
determin
mab
denomin
display
high
protect
titer
iumg
mab
show
extrem
potent
neutral
activ
vitro
model
hbv
infect
use
primari
hepatocyt
tupaia
belangeri
target
recombin
variabl
heavi
light
domain
sequenc
deriv
mab
clone
eukaryot
express
vector
show
ident
fine
specif
log
higher
titer
origin
envisag
mab
abl
effici
prevent
hbv
reinfect
liver
transplant
endstag
chronic
hbv
infect
infect
needlestick
exposur
provid
unlimit
sourc
valuabl
protect
antihb
antibodi
hepat
b
viru
hbv
one
world
common
infecti
agent
caus
million
infect
year
peopl
die
year
chronic
infectionrel
cirrhosi
hepatocellular
carcinoma
hcc
fulmin
hepat
b
transmiss
occur
via
percutan
mucos
exposur
infecti
bodi
fluid
therefor
common
rout
transmiss
sexual
transmiss
howev
infect
blood
transfus
blood
product
complet
elimin
contamin
inject
medic
procedur
share
needl
syring
paraphernalia
among
intraven
drug
user
still
repres
major
public
health
problem
vertic
transmiss
common
especi
asia
hbv
titer
matern
blood
high
develop
countri
yet
implement
hepat
b
vaccin
hbv
pose
risk
healthcar
worker
expos
accident
needlestick
injuri
current
market
hepat
b
vaccin
contain
major
viral
envelop
protein
hepat
b
surfac
antigen
hbsag
vaccin
hbsag
provid
protect
hbv
infect
prevent
complic
includ
liver
cirrhosi
hcc
control
eventu
elimin
hbv
infect
possibl
appropri
use
hepat
b
vaccin
reduc
significantli
diseas
burden
associ
cost
although
prevent
hbv
infect
may
effect
achiev
vaccin
certain
situat
requir
differ
prophylact
approach
liver
transplant
endstag
hbvrelat
liver
diseas
one
exampl
hepat
b
immun
globulin
hbig
play
central
role
prophylaxi
recurr
hepat
b
patient
undergo
liver
transplant
prior
routin
use
hbig
immunoprophylaxi
recurr
hbv
liver
allograft
occur
infrequ
associ
aggress
fibros
cholestat
variant
caus
progress
graft
dysfunct
signific
mortal
subsequ
avail
safe
effect
antivir
drug
led
addit
surviv
benefit
improv
prophylact
efficaci
prevent
diseas
progress
recurr
hbig
polyclon
antibodi
hbv
surfac
antigen
hbsag
deriv
pool
human
plasma
although
mechan
action
yet
complet
understood
thought
hbig
act
circul
prevent
hepatocyt
infect
bind
neutral
circul
virion
express
hbsag
perhap
induc
lysi
infect
cell
within
liver
hbig
may
also
prevent
celltocel
infect
well
reduc
hbsag
virion
secret
upon
endocytosi
hepatocyt
provid
maxim
protect
reinfect
liver
graft
hbig
given
frequent
typic
daili
week
follow
transplant
pivot
multicent
european
trial
demonstr
long
term
administr
intraven
iv
hbig
reduc
hepat
b
recurr
rate
associ
improv
graft
patient
surviv
subsequ
trial
use
variabl
schedul
hbig
administr
confirm
efficaci
hbig
monotherapi
recurr
hbv
infect
hbig
prophylaxi
expens
hbig
commonli
administ
intraven
high
dose
daili
first
week
monthli
thereaft
make
current
cost
manag
patient
transplant
hbvrelat
cirrhosi
prohibit
even
develop
countri
dose
reduct
propos
cost
reduct
either
base
flat
dose
responseguid
basi
order
maintain
circul
antihb
protect
level
howev
hbig
dose
variabl
individu
among
patient
also
propos
abandon
hbig
prophylaxi
favor
use
antivir
drug
alon
howev
controversi
issu
cost
hbig
treatment
prevent
limit
use
addit
limit
includ
follow
suppli
limit
depend
vaccin
human
donor
exhibit
high
titer
protect
antihb
ii
purif
time
consum
must
undergo
lengthi
virusinactiv
procedur
iii
antihb
titer
variabl
effect
viru
neutral
effici
larg
unknown
exclus
base
arbitrarili
protect
antihb
serum
titer
iv
polyclon
immunoglobulin
includ
sever
antibodi
specif
may
select
hbv
mutant
resist
current
avail
antivir
drug
v
hbig
prepar
current
combin
antivir
drug
insur
complet
protect
thu
ad
cost
paper
describ
product
character
human
monoclon
antibodi
humab
specif
hbv
major
envelop
protein
one
humab
recogn
conform
epitop
locat
common
determin
neutral
hbv
high
effici
vitro
use
hbvsuscept
primari
hepatocyt
tupaia
belangeri
pth
believ
humab
offer
mani
advantag
commerci
avail
plasmaderiv
hbig
test
vivo
protect
hbv
reinfect
follow
liver
transplant
gener
postexposur
prophylaxi
hepat
b
studi
approv
institut
review
board
policlinico
san
matteo
itali
particip
administ
written
inform
consent
sign
conserv
file
studi
compli
recommend
declar
helsinki
peripher
blood
mononuclear
cell
pbmc
obtain
vaccin
healthi
donor
adri
person
convalesc
acut
hepat
b
pk
subject
show
high
serum
antihb
titer
pbmc
isol
standard
densiti
gradient
centrifug
b
cell
neg
purifi
use
b
cell
isol
kit
ii
code
macsmiltenyi
biotec
b
cell
ml
puriti
incub
vv
undilut
supernat
ebvproduct
marmoset
cell
line
h
co
wash
incub
complet
media
consist
dutch
mod
code
sigma
supplement
fetal
bovin
serum
code
hyclon
lglutamin
code
sigma
napyruv
code
sigma
mem
nonessenti
aminoacid
code
sigma
antibioticantimycot
solut
code
sigma
microsynt
ngml
code
r
system
describ
minor
modif
consist
omit
enrich
memori
b
cell
x
b
cell
complet
media
seed
well
roundbottom
plate
code
costar
presenc
irradi
feeder
cell
incub
day
ad
final
concentr
ngml
evid
visual
outgrowth
lymphoblastoid
cell
supernat
test
elisa
presenc
antihbv
envelop
antibodi
use
recombin
hbsag
prepar
cultur
exhibit
nm
optic
densiti
clone
subclon
limit
dilut
complet
media
ngml
presenc
irradi
feeder
cell
obtain
stabl
agspecif
bcell
clone
gener
procedur
obtain
human
hcvspecif
bcell
clone
pbmc
extens
describ
previous
perform
test
bcell
clone
supernat
standard
elisa
use
recombin
hbsag
prepar
contain
protein
stabl
clone
supernat
also
examin
western
blot
use
recombin
denatur
hbsag
ag
bind
common
determin
polypeptid
determin
competit
elisa
use
murin
mab
cosmo
bio
co
ltd
code
cosmo
bio
co
ltd
specif
region
briefli
microtit
plate
coat
hbsag
concentr
bicarbon
buffer
ph
per
ml
overnight
satur
pb
contain
bovin
serum
albumin
bsa
murin
monoclon
antibodi
dilut
concentr
ngwell
incub
increas
concentr
ngw
human
monoclon
antibodi
correspond
recombin
h
plate
wash
pb
dilut
hrpaffinipuregoat
antimous
igg
hl
code
jacksonimmunoresearch
bsapb
ad
incub
h
wash
pb
opd
solut
code
dako
ad
od
measur
humab
antihcv
antihbv
use
neg
control
wherea
alon
use
posit
control
perform
extens
describ
briefli
primari
tupaia
belangeri
hepatocyt
cultur
pth
shown
suscept
hbv
vivo
vitro
inocul
purifi
hbv
human
serum
ratio
hbv
genomehepatocyt
permiss
use
primari
hepatocyt
tupaia
belangeri
obtain
institut
review
board
justusliebig
univers
giessen
anim
handl
accord
ethic
rule
anim
care
determin
whether
infect
pth
hbv
could
prevent
human
antihb
mab
hbv
preincub
three
differ
human
mab
dilut
rang
neutral
power
human
antihb
mab
directli
compar
wellcharacter
antibodi
previous
shown
exhibit
signific
neutral
activ
pth
vitro
infect
assay
readout
success
hbvinfect
cultur
newli
produc
hbsag
day
infect
neutral
complet
viral
protein
product
detect
cultur
supernat
variabl
heavi
light
domain
sequenc
obtain
describ
clone
eukaryot
express
vector
modiquest
research
proprietari
procedur
recombin
antibodi
produc
transient
transfect
cell
modiquest
research
proprietari
procedur
next
recombin
spent
cultur
supernat
recombin
mab
valid
hbsag
elisa
duplic
use
supernat
origin
bcell
clone
compar
end
hbsag
coat
carbon
buffer
elisa
plate
follow
block
serial
dilut
allow
bind
room
temperatur
duplic
recombin
cultur
sup
human
mab
antihb
complet
medium
neg
control
plate
wash
bound
ab
visual
use
goat
antihuman
igghrp
tmb
extinct
read
nm
three
human
bcell
clone
sever
subclon
deriv
two
subject
mention
materi
method
humab
igg
show
strong
bind
hbsag
elisa
fig
secret
wherea
secret
western
blot
analysi
show
recogn
sequenti
denaturationinsensit
epitop
locat
within
band
correspond
expect
molecular
weight
kda
major
envelop
protein
wherea
bind
protein
band
indic
recogn
denaturationsensit
conform
epitop
fig
competit
elisa
show
recombin
bind
hbsag
almost
complet
inhibit
addit
murin
mab
specif
hbsag
common
determin
fig
bind
hbsag
significantli
affect
mab
fig
mab
neutral
activ
analyz
adriand
pkderiv
humab
use
neutral
assay
describ
supernat
show
strong
neutral
activ
dilut
sinc
specif
concentr
supernat
extrapol
effici
neutral
hbv
concentr
least
ngml
fig
sinc
viral
inoculum
use
infect
pth
ml
deriv
ngml
suffici
neutral
hbv
particl
pk
humab
supernat
show
contrast
behavior
thu
neutral
infect
pth
show
moder
neutral
activ
dilut
ngml
prove
least
good
standard
murin
mab
use
posit
neutral
standard
correspond
concentr
fig
sinc
show
potent
hbv
neutral
activ
cdna
vh
sequenc
cdna
vl
sequenc
obtain
clone
clone
respect
result
vh
vl
domain
sequenc
sens
antisens
direct
n
vh
n
vl
cdna
clone
race
reaction
rna
isol
human
bcell
clone
yield
clear
sequenc
vh
vl
domain
n
ident
sequenc
respect
individu
point
mutat
detect
sequenc
file
individu
clone
ambigu
solitari
occurr
otherwis
unambigu
sequenc
align
like
caus
erron
insert
base
polymeras
chain
reaction
bia
sequenc
reaction
sequenc
perform
opposit
direct
ie
two
sequenc
reaction
obtain
per
clone
fulllength
cdna
obviou
sequenc
analyz
germlin
align
allow
identif
complementar
determin
region
cdr
determin
specif
hbsag
vh
vl
sequenc
clone
avail
fig
eukaryot
express
yield
recombin
specif
ident
origin
clone
vh
vl
sequenc
ident
repres
vh
vl
sequenc
clone
eukaryot
express
vector
describ
recombin
prove
reactiv
toward
target
antigen
interestingli
recombin
spent
cultur
supernat
display
reactiv
approxim
one
log
scale
spent
cultur
supernat
origin
human
bcell
clone
detail
fig
therefor
experi
conclus
show
recombin
could
clone
produc
reactiv
toward
target
antigen
hbsag
could
valid
elisa
unmet
medic
need
sustain
reagent
allow
standard
immunoprophylaxi
hbv
reinfect
liver
transplant
set
standard
reagent
could
also
benefici
use
set
acut
treatment
accident
needlestick
prevent
verticalperinat
hbv
transmiss
administr
antihb
antibodi
usual
perform
prophylact
measur
wait
full
develop
vaccineinduc
adapt
immun
hbv
end
sever
mab
propos
develop
order
address
need
mab
hbv
murin
origin
murin
antibodi
inher
disadvantag
evok
immun
reaction
human
recipi
use
therapeut
prophylact
composit
humab
capabl
neutral
hbv
infect
also
describ
instanc
two
humab
term
obtain
pbmc
hbv
vaccin
individu
engraft
trimera
mous
model
describ
specif
activ
iumg
iumg
respect
anoth
seri
humab
describ
tajiri
et
al
humab
deriv
human
vhvl
chain
fragment
b
cell
vaccin
person
clone
vector
howev
seem
provid
full
protect
hbv
infect
vitro
even
highest
concentr
test
provid
still
residu
activ
neutral
hbv
humab
test
anoth
humab
describ
shin
et
al
abl
fulli
prevent
hbv
infect
two
chimpanze
mix
hbv
humab
construct
phagedisplay
ab
librari
convert
human
report
titer
iumg
report
gener
three
fulli
human
mab
obtain
clone
b
cell
one
patient
convalesc
acut
hepat
b
one
vaccin
individu
recogn
major
protein
hbv
latter
show
extrem
high
protect
antihb
titer
recogn
conform
epitop
within
common
determin
hbsag
importantli
show
high
neutral
capac
vitro
hbv
infect
system
use
pth
target
potenc
humab
iumg
ig
exce
log
best
previous
describ
mab
iumg
ig
moreov
fulli
human
directli
produc
secret
bcell
clone
without
prior
variabl
chain
fragment
clone
construct
phagedisplay
ab
librari
one
potenti
problem
prevent
hbv
infect
reinfect
emerg
hbsag
escap
mutant
describ
minor
patient
hbig
prophylaxi
liver
transplant
emerg
result
select
immun
problem
larg
overcom
maintain
high
titer
neutral
antibodi
achiev
potent
mab
one
describ
herein
problem
may
circumv
prepar
pool
mab
although
would
extrem
difficult
achiev
work
human
mab
sinc
common
determin
domin
epitop
tend
monopol
specif
immun
respons
complex
protein
inde
origin
antigen
sin
first
describ
phenomenon
sequenti
exposur
viral
variant
induc
preferenti
antibodi
respons
domin
viru
strain
encount
past
result
respons
minor
strain
diminish
humab
present
herein
particular
may
advantag
use
treat
prevent
hbv
infect
neutral
hbv
effici
effect
due
extrem
potenc
mab
may
administ
low
quantiti
thu
contribut
costeffect
treatment
gener
antibodi
may
prefer
administ
human
order
maintain
serum
level
iul
serum
consid
protect
avoid
reinfect
engraft
liver
convent
protect
titer
antihb
vaccin
person
arbitrarili
set
iul
moreov
variabl
domain
may
advantag
use
produc
unlimit
amount
humab
without
reli
vaccin
donor
plasma
well
recombin
antibodi
bind
molecul
effect
treatment
prevent
hbv
infect
would
desir
mab
produc
gmp
condit
use
clinic
trial
prophylaxi
hbv
reinfect
follow
liver
transplant
prevent
hbv
infect
follow
needlestick
exposur
